Roche’s Ipatasertib Promising In Prostate, But Disappointing In Breast Cancer

Mixed Results In Pivotal Trials

 
• By Andrew McConaghie

Roche is hoping the investigational oral drug can help it expand its presence in breast cancer and break into the prostate cancer market – but the signals are decidedly mixed.

Metro
The ESMO congress had been planned to take place in Madrid this year, but like other meetings, went virtual because of the coronavirus pandemic.

More from Business

More from Scrip